A137310 Stock Overview
An in-vitro diagnostic company, provides point-of-care diagnostic solutions in South Korea and internationally.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 2/6 |
SD Biosensor, Inc Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₩13,250.00 |
52 Week High | ₩13,600.00 |
52 Week Low | ₩8,650.00 |
Beta | 1.09 |
11 Month Change | 42.78% |
3 Month Change | 22.57% |
1 Year Change | 9.69% |
33 Year Change | -77.54% |
5 Year Change | n/a |
Change since IPO | -78.28% |
Recent News & Updates
Would SD Biosensor (KRX:137310) Be Better Off With Less Debt?
Aug 08Insufficient Growth At SD Biosensor, Inc (KRX:137310) Hampers Share Price
Jul 03Insufficient Growth At SD Biosensor, Inc (KRX:137310) Hampers Share Price
Feb 28Shareholder Returns
A137310 | KR Medical Equipment | KR Market | |
---|---|---|---|
7D | 48.0% | 4.4% | -3.1% |
1Y | 9.7% | 16.6% | -2.4% |
Return vs Industry: A137310 underperformed the KR Medical Equipment industry which returned 16.6% over the past year.
Return vs Market: A137310 exceeded the KR Market which returned -2.4% over the past year.
Price Volatility
A137310 volatility | |
---|---|
A137310 Average Weekly Movement | 8.3% |
Medical Equipment Industry Average Movement | 8.2% |
Market Average Movement | 6.4% |
10% most volatile stocks in KR Market | 11.9% |
10% least volatile stocks in KR Market | 3.4% |
Stable Share Price: A137310's share price has been volatile over the past 3 months.
Volatility Over Time: A137310's weekly volatility (8%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2010 | 576 | Hyo Keun Lee | www.sdbiosensor.com |
SD Biosensor, Inc, an in-vitro diagnostic company, provides point-of-care diagnostic solutions in South Korea and internationally. The company’s products include STANDARD Q, which provides various rapid test parameters comprising COVID-19 products and other parameters; STANDARD F, a multi-parametric and random accessible FIA system that provides diagnostic results to the laboratories; and STANDARD E, an enzyme linked immunosorbent assay for mass screening tests. Its products also include STANDARD M, a point-of-care MDx system for clinical decision making near-the-patient, which include analyzers, assay menus, qPCR reagents, and NA extraction kits; procell Dx, an in vitro diagnostic products for the diagnosis of infectious disease, such as tuberculosis and SARS-CoV-2, and for checking the immune status of individuals through the interferon gamma release assay; and blood glucose meters.
SD Biosensor, Inc Fundamentals Summary
A137310 fundamental statistics | |
---|---|
Market cap | ₩1.62t |
Earnings (TTM) | -₩256.18b |
Revenue (TTM) | ₩649.67b |
2.5x
P/S Ratio-6.3x
P/E RatioIs A137310 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
A137310 income statement (TTM) | |
---|---|
Revenue | ₩649.67b |
Cost of Revenue | ₩417.21b |
Gross Profit | ₩232.46b |
Other Expenses | ₩488.64b |
Earnings | -₩256.18b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -2.09k |
Gross Margin | 35.78% |
Net Profit Margin | -39.43% |
Debt/Equity Ratio | 17.2% |
How did A137310 perform over the long term?
See historical performance and comparison